ERBB2 and breast carcinoma: For example, differentiation among breast cancer cells with different receptor status by the basal mitochondrial redox ratio [18], identification of glycolytic levels, subtypes, and early-treatment response in breast cancer cells [19], detection of the effects of HER2 overexpression on breast cancer cell metabolism and treatment response [20], identification of tumor cell-cycle status [21] and singling out drug-responsive from drug-resistant cells [22].